United States Cardiovascular Devices Market Size, Share, Trends and Forecast 2026-2034 | Market to Reach US$32.62 Billion as AI Monitoring and Minimally Invasive Care Accelerate
Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "United States Cardiovascular Devices Market Report by Device Type, Application, End User, States and Company Analysis 2026-2034" has been added to ResearchAndMarkets.com's offering.
The United States cardiovascular devices market is projected to grow from US$ 18.79 Billion in 2025 to US$ 32.62 Billion by 2034, registering a Compound Annual Growth Rate (CAGR) of 6.32% from 2026-2034. Market expansion is supported by the increasing prevalence of cardiovascular diseases, an aging population, rising healthcare expenditure, favorable reimbursement coverage, and growing demand for minimally invasive procedures.
Cardiovascular devices used across the United States include pacemakers, stents, defibrillators, catheters, heart valves, cardiac monitoring systems, ventricular assist devices, and cardiac resynchronization therapy devices. Strong healthcare infrastructure, specialized cardiac facilities, early diagnosis initiatives, and continued investment in medical technology are accelerating the adoption of these products.
Rising Cardiovascular Disease Burden
Cardiovascular diseases remain a leading cause of mortality, creating sustained demand for diagnostic, monitoring, therapeutic, and surgical devices. Coronary artery disease, heart failure, and arrhythmias are becoming more prevalent due to obesity, smoking, physical inactivity, hypertension, diabetes, unhealthy diets, and stress. As patient volumes increase, hospitals and healthcare providers are investing in advanced cardiovascular technologies to support early detection, continuous monitoring, and effective treatment.
Technological Innovation and Minimally Invasive Care
Innovation is transforming the United States cardiovascular devices market through implantable pacemakers, drug-eluting stents, wearable heart monitors, advanced catheters, artificial intelligence-enabled diagnostic platforms, and remote patient monitoring systems. Minimally invasive procedures can reduce hospital stays, recovery periods, and complication risks while improving treatment efficiency.
Wireless connectivity and cloud-based monitoring also allow healthcare professionals to evaluate patient data remotely and respond quickly to potential complications. Recent industry developments include FDA approval of the Johnson & Johnson MedTech VARIPULSE Pulsed Field Ablation system in November 2024 and FDA approval of the Boston Scientific FARAPULSE Pulsed Field Ablation System in January 2024. AliveCor also introduced its AI-supported Kardia 12L ECG System in June 2024.
Aging Population and Healthcare Spending
The expanding elderly population is increasing demand for cardiovascular diagnostic and therapeutic devices. The number of Americans aged 65 years and older is expected to reach approximately 80 million by 2040, while the population aged 85 years and older is projected to rise substantially. Older adults face higher risks of arrhythmias, heart failure, coronary artery disease, and other chronic conditions requiring ongoing cardiac care.
High healthcare expenditure, insurance coverage, government-sponsored programs, preventive screenings, and access to specialized treatment facilities further support market growth. Hospitals, clinics, diagnostic centers, ambulatory surgical centers, and cardiac catheterization laboratories continue to invest in modern cardiovascular equipment.
Market Challenges
High device and procedure costs remain a major barrier. Implantable defibrillators, pacemakers, stents, heart valves, and related interventions can generate significant expenses for patients, hospitals, insurers, and government healthcare programs. Budget limitations may restrict access to newer technologies, particularly at smaller healthcare facilities.
Manufacturers must also comply with strict United States regulatory requirements covering clinical testing, safety, efficacy, manufacturing quality, and post-market surveillance. Lengthy and expensive approval processes may delay product launches, while device defects can result in recalls, litigation, and reputational damage. These pressures are particularly challenging for smaller companies with limited financial and technical resources.
Major Market Segments
The cardiovascular diagnostic and monitoring devices segment is expanding as demand rises for ECG systems, Holter monitors, cardiac event monitors, imaging platforms, and wearable technologies. Continuous and remote monitoring solutions are gaining adoption because they support preventive care and timely clinical intervention.
Cardiac arrhythmia devices, including pacemakers, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices, are expected to record sustained demand. The heart failure devices segment is also advancing through improvements in ventricular assist devices, heart pumps, and implantable cardiac support technologies.
Hospitals and clinics represent the largest end-user segment because they perform complex cardiac procedures and provide specialized inpatient and outpatient care. Diagnostic centers are also increasing their use of ECG machines, stress testing equipment, cardiac imaging systems, and outpatient monitoring technologies.
Regional Market Outlook
California is a leading state market due to its large population, extensive hospital network, medical technology companies, and strong research ecosystem. New York benefits from major academic medical centers, advanced cardiac facilities, and high demand for diagnostic and therapeutic procedures. Washington is experiencing increased adoption of wearable devices, digital health platforms, and remote cardiovascular monitoring. Massachusetts remains an important innovation center because of its internationally recognized hospitals, research institutions, biotechnology companies, and medical device developers.
Market Segmentation
Competitive Landscape
Leading companies in the United States cardiovascular devices market include Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences, Cardinal Health Inc., Medtronic PLC, GE Healthcare, Johnson & Johnson Services, Inc., and Siemens Healthcare GmbH. Competitive analysis covers company overviews, key personnel, recent developments, SWOT analysis, and revenue performance.
Key Attributes
Key Topics Covered
1. Introduction
2. Research & Methodology
2.1 Data Source
2.1.1 Primary Sources
2.1.2 Secondary Sources
2.2 Research Approach
2.2.1 Top-Down Approach
2.2.2 Bottom-Up Approach
2.3 Forecast Projection Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. United States Cardiovascular Devices Market
5.1 Historical Market
5.2 Market Forecast
6. Market Share Analysis
6.1 By Device Type
6.2 By Application
6.3 By End User
6.4 By States
7. Device Type
7.1 Historical and Forecast Analysis by Device Type
7.1.1 Diagnostic and Monitoring Devices
7.1.2 Therapeutic and Surgical Devices
8. Application
8.1 Historical and Forecast Analysis by Application
8.1.1 Coronary Artery Disease (CAD)
8.1.2 Cardiac Arrhythmia
8.1.3 Heart Failure
8.1.4 Others
9. End User
9.1 Historical and Forecast Analysis by End User
9.1.1 Hospitals and Clinics
9.1.2 Ambulatory Surgical Centers
9.1.3 Diagnostic Centers
9.1.4 Cardiac Catheterization Laboratories
9.1.5 Others
10. States
10.1 Historical and Forecast Analysis by State
10.1.1 California
10.1.2 Texas
10.1.3 New York
10.1.4 Florida
10.1.5 Illinois
10.1.6 Pennsylvania
10.1.7 Ohio
10.1.8 Georgia
10.1.9 New Jersey
10.1.10 Washington
10.1.11 North Carolina
10.1.12 Massachusetts
10.1.13 Virginia
10.1.14 Michigan
10.1.15 Maryland
10.1.16 Colorado
10.1.17 Tennessee
10.1.18 Indiana
10.1.19 Arizona
10.1.20 Minnesota
10.1.21 Wisconsin
10.1.22 Missouri
10.1.23 Connecticut
10.1.24 South Carolina
10.1.25 Oregon
10.1.26 Louisiana
10.1.27 Alabama
10.1.28 Kentucky
10.1.29 Rest of United States
11. Porter's Five Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes
12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat
13. Key Players Analysis
13.1 Company Profile Scope
13.1.1 Overview
13.1.2 Key Person
13.1.3 Recent Developments
13.1.4 Company SWOT
13.1.5 Revenue Analysis
13.2 Companies Covered
13.2.1 Abbott Laboratories
13.2.2 Boston Scientific Corporation
13.2.3 Edwards Lifesciences
13.2.4 Cardinal Health Inc.
13.2.5 Medtronic PLC
13.2.6 GE Healthcare
13.2.7 Johnson & Johnson Services, Inc.
13.2.8 Siemens Healthcare GmbH
For more information about this report visit https://www.researchandmarkets.com/r/7y56ir
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.